Physician profile
Hannah E Noger
NPI 1598314726
$8,579.36
in general payments reported to CMS, 2019-2025
23 companies · $3,100 in 2025
The $3,100 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $175 · 2023: $1,601 · 2024: $3,703 · 2025: $3,100.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,393 · Education: $1,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,393.45 |
| Education | $1,010.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $1,558.88 | 2023-2025 | Ilumya |
| Abbvie INC. | $1,417.57 | 2023-2025 | |
| Janssen Biotech, INC. | $1,305.22 | 2023-2025 | Tremfya |
| Amgen INC. | $763.27 | 2023-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $616.79 | 2023-2025 | Dupixent |
| Ucb, INC. | $404.30 | 2023-2025 | Bimzelx, Cimzia |
| Arcutis Biotherapeutics, INC. | $309.54 | 2024-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $308.62 | 2023-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $297.40 | 2024-2025 | |
| Galderma Laboratories, L.P. | $276.16 | 2024-2025 | Nemluvio, Aklief |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.76 | 2023-2024 | Spevigo |
| Leo Pharma INC. | $178.12 | 2024-2025 | Adbry, Spevigo, Anzupgo |
| Choice Spine, LLC | $175.15 | 2021 | |
| Genzyme Corporation | $164.04 | 2024-2025 | |
| Incyte Corporation | $149.30 | 2024 | Opzelura |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $140.34 | 2023-2025 | Taltz, Olumiant, Ebglyss |
| Dermavant Sciences, INC. | $70.90 | 2023-2024 | Vtama |
| Pfizer INC. | $66.40 | 2023-2025 | |
| Convatec INC. | $62.29 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $45.02 | 2023 | |
| Verrica Pharmaceuticals INC. | $15.82 | 2024 | Ycanth |
| Solta Medical, A Division of Bausch Health US, LLC | $14.85 | 2024 | Clear+Brilliant |
| Organon LLC | $9.62 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hannah Noger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.